BioSpace News Archive

Exelixis, Inc. reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022.

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter ended June 30, 2022.

Masimo announced its financial results for the second quarter of 2022, ended July 2, 2022.

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”) , a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2022.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous (IV) formulation of TPOXX treatment courses valued at approximately $26 million.

MediWound Ltd. today announced financial results for the second quarter ending June 30, 2022.

Intra-Cellular Therapies, Inc. today announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.

InMed Pharmaceuticals Inc. is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately.

Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced pipeline and business updates and reported financial results for the second quarter ended June 30, 2022.